<DOC>
	<DOCNO>NCT02750410</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety combination therapy dulaglutide insulin Japanese participant type 2 diabetes .</brief_summary>
	<brief_title>A Study Dulaglutide Japanese Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Participants diagnosis type 2 diabetes mellitus Participants treat insulin therapy ( basal insulin , premixed insulin , basal/mealtime insulin regimen ) without 1 2 oral antidiabetic ( OADs ) stable dose least 3 month screen Participants HbA1c value ≥7.0 % ≤10.5 % screen participant wash OADs ( dipeptidyl peptidase4 [ DPP4 ] inhibitor , sulfonylurea [ SU ] , glinides ) ≥7.5 % ≤10.5 % screen participant wash OADs Participants stable weight ( ±5 % ) ≥3 month prior screen Participants body mass index ( BMI ) 18.5 35.0 kilogram per meter square ( kg/m^2 ) Participants diagnosis type 1 diabetes Participants previously receive therapy glucagonlike peptide1 receptor agonist within 3 month prior screen Participants previously treat dulaglutide prior screen Participants treat 2 follow screening : DPP4 inhibitor , SU , glinide ( ie , DPP4 inhibitor SU , DPP4 inhibitor glinide ) Participants treat continuous subcutaneous insulin infusion ( CSII ) screen Participants clinically significant gastric empty abnormality , hepatitis , pancreatitis , renal dysfunction , thyroid abnormality Participants history clinically significant cardiovascular disease , transplant organ , active untreated malignancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>